Bristol Myers Squibb (BMY) must once again defend itself against claims that it delayed regulatory approvals for key medicines to avoid a multibillion-dollar payout to former Celgene investors, after a US appeals court revived a lawsuit previously dismissed in 2024.

Jazz Pharmaceuticals (JAZZ) said it would acquire privately held Actio Biosciences in a transaction valued at up to $1.32bn, adding a clinical-stage treatment for a severe rare epilepsy with no approved therapies to its neuroscience portfolio.

Hims & Hers Health (HIMS) posted a wider-than-expected second-quarter loss as its shift toward branded weight-loss drugs drove up costs, rattling investors despite the company lifting its full-year revenue guidance.

BridgeBio Pharma (BBIO) is closing in on blockbuster territory with its transthyretin amyloidosis drug Attruby, after second-quarter US sales of $222mn beat Wall Street consensus by six per cent, prompting Jefferies analysts to forecast the drug could surpass $1bn in annual global sales this year.

Cardinal Health (CAH), the Dublin, Ohio-based drug distributor, raised its full-year profit outlook above analyst expectations after delivering a stronger-than-expected fourth quarter, buoyed by sustained demand for specialty and branded pharmaceuticals.

Tenax Therapeutics (TENX) said its experimental drug TNX-103 failed to significantly improve walking capacity versus placebo in a late-stage trial for a difficult-to-treat form of heart failure, sending its shares down nearly 90%.

Exor (EXOR), the investment vehicle of Italy's Agnelli family, has updated its shareholder agreement with Philips (PHG) to permit it to increase its holding in the Dutch health technology company to as much as 22%, up from a previous ceiling of 20%.

The US Food and Drug Administration has taken steps to increase oversight of food additives, issuing a proposed rule that would require manufacturers to formally notify the agency when they determine an ingredient to be "Generally Recognized as Safe," or GRAS.

A drug generating more than $1bn in quarterly sales might ordinarily be cause for celebration. But when Alnylam Pharmaceuticals (ALNY) reported $1.01bn in second-quarter Amvuttra revenues — fractionally below published consensus estimates — and trimmed its full-year outlook for the broader transthyretin franchise, its shares tumbled nearly 30%.

Alcon (ALC) raised its full-year profitability target last month after benefiting from US tariff refunds, sending its shares up around 4% in early trading and to the top of Europe's benchmark Stoxx 600 index.

Zydus Lifesciences (ZYDU) reported a near-third drop in first-quarter profit last month, as surging costs erased the benefit of robust sales growth across its domestic and consumer wellness operations.

Curium, the private equity-backed radiopharmaceutical company, has agreed to acquire Lantheus Holdings (LNTH) for up to $8bn, marking one of the sector's largest transactions as demand for radioactive compounds used in cancer diagnosis and treatment continues to attract intense dealmaking interest.

California's highest court has ruled in favor of Gilead Sciences (GILD), dismissing negligence claims brought by an estimated 24,000 HIV patients in a closely watched case that tested whether drugmakers can be held liable for failing to develop safer alternatives to treatments already deemed effective.

KKR (KKR) has agreed to acquire medical-device manufacturer Integer Holdings (ITGR) in an all-cash transaction valued at approximately $5.7bn, adding a critical supplier to the medtech industry to its expanding healthcare portfolio.

Supernus Pharmaceuticals (SUPN) and Indivior (INDV) have agreed to merge in an all-stock transaction to form a central nervous system-focused biopharma, the companies announced, combining five growth-stage products and a combined market capitalization of $7.5bn.

AbbVie (ABBV) slightly reduced its 2026 earnings forecast to account for its planned acquisition of Apogee Therapeutics, even as the drugmaker surpassed second-quarter expectations on the back of robust immunology drug sales.

Vertex Pharmaceuticals (VRTX) raised the upper end of its full-year revenue forecast, citing robust demand across its cystic fibrosis portfolio after second-quarter sales came in ahead of Wall Street expectations.

Moderna (MRNA) posted stronger-than-expected second-quarter revenue, buoyed by vaccine partnership payments and overseas sales of its COVID-19 shot, as the company awaits a decision that could mark the most significant expansion of its mRNA platform since the pandemic.

AstraZeneca (AZN) shares fell sharply after reports emerged of merger talks with US rival Bristol Myers Squibb (BMY), with investors delivering a swift verdict that the British pharmaceutical giant has little need for a deal that would create one of the world's largest drugmakers.

Shares of Alnylam Pharmaceuticals (ALNY) hit a 52-week low of $273.03 last month, extending a steep decline that has seen the RNAi drug developer shed nearly 29% of its value since the start of the year.